Mallinckrodt CEO fights back against Citron Research claims

Mark Trudeau, CEO of Mallinckrodt Pharmaceuticals | Photo courtesy of Creative Commons
Mark Trudeau, CEO of Mallinckrodt Pharmaceuticals | Photo courtesy of Creative Commons

Mark Trudeau, CEO of Mallinckrodt Pharmaceuticals, appeared on CNBC’s Squawk Box to calm investor fears after the company’s stock dropped nearly 26 percent Monday.

Mallinckrodt stock values plummeted following a tweet Monday by noted short seller Citron Research.

Trudeau told CNBC that he rejected Citron’s contention that it would face challenges being reimbursed for a high-priced specialty drug.

Andrew Left of Citron, who accused Mallinckrodt of being an offender of the reimbursement system, said in an interview with CNBC that Trudeau misrepresented the efficacy of the drug maker’s biggest producer, Acthar. Trudeau called the accusations “completely false.”

Read more from the St. Louis Business Journal and St. Louis Post-Dispatch


Tags:, , ,

Leave a Reply

Have you heard?

Missouri Business Alert is participating in CoMoGives2019!

Find out how we plan to use your gift to enhance training and programming for our students